$NURO
NeuroMetrix, Inc. Stock $nuro

$nuro Overview Financials Valuation SEC Filings Company Website

2017 Q1 Form 10-Q Financial Statement

#000162828017003952 Filed on April 20, 2017

Income Statement

Concept	2017 Q1	2016 Q1
Revenue	$4.306M	$2.275M
YoY Change	89.26%	77.34%
Cost Of Revenue	$2.698M	$1.483M
YoY Change	81.96%	132.64%
Gross Profit	$1.671M	$792.7K
YoY Change	110.75%	22.77%
Gross Profit Margin	38.8%	34.84%
Selling, General & Admin	$4.019M	$3.832M
YoY Change	4.89%	27.67%
% of Gross Profit	240.59%	483.42%
Research & Development	$903.3K	$1.157M
YoY Change	-21.91%	28.17%
% of Gross Profit	54.07%	145.92%
Depreciation & Amortization	$61.58K	$61.64K
YoY Change	-0.1%	111.49%
% of Gross Profit	3.69%	7.78%
Operating Expenses	$4.923M	$4.989M
YoY Change	-1.33%	27.78%
Operating Profit	-$3.314M	-$4.196M
YoY Change	-21.02%	28.77%
Interest Expense	$80.00K	$100.0K
YoY Change	-20.0%	-91.6%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$3.230M	-$4.100M
YoY Change	-21.22%	98.07%
Income Tax
% Of Pretax Income
Net Earnings	-$3.232M	-$4.095M
YoY Change	-21.07%	97.72%
Net Earnings / Revenue	-75.07%	-179.99%
Basic Earnings Per Share	-$7.27
Diluted Earnings Per Share	-$7.27	-$82.00M
COMMON SHARES
Basic Shares Outstanding	1.001M shares	4.050M shares
Diluted Shares Outstanding	1.001M shares

Balance Sheet

Concept	2017 Q1	2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$6.900M	$8.740M
YoY Change	-21.05%	36.56%
Cash & Equivalents	$6.897M	$8.740M
Short-Term Investments
Other Short-Term Assets	$1.420M	$720.0K
YoY Change	97.22%	176.92%
Inventory	$1.197M	$1.510M
Prepaid Expenses
Receivables	$950.0K	$490.0K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$10.46M	$11.46M
YoY Change	-8.69%	39.37%
LONG-TERM ASSETS
Property, Plant & Equipment	$471.1K	$650.0K
YoY Change	-27.52%	20.43%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$150.0K	$190.0K
YoY Change	-21.05%	-48.65%
Total Long-Term Assets	$625.5K	$850.0K
YoY Change	-26.41%	-6.4%
TOTAL ASSETS
Total Short-Term Assets	$10.46M	$11.46M
Total Long-Term Assets	$625.5K	$850.0K
Total Assets	$11.09M	$12.31M
YoY Change	-9.92%	34.82%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$404.1K	$1.380M
YoY Change	-70.72%	50.57%
Accrued Expenses	$1.395M	$1.880M
YoY Change	-25.8%	46.17%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.065M	$3.270M
YoY Change	-6.26%	-1.47%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$170.0K	$190.0K
YoY Change	-10.53%	-95.4%
Total Long-Term Liabilities	$170.0K	$190.0K
YoY Change	-10.53%	-95.4%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.065M	$3.270M
Total Long-Term Liabilities	$170.0K	$190.0K
Total Liabilities	$3.237M	$3.460M
YoY Change	-6.44%	-53.55%
SHAREHOLDERS EQUITY
Retained Earnings	-$181.7M
YoY Change
Common Stock	$874.00	$439.00
YoY Change	99.09%	-48.47%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$7.852M	$8.850M
YoY Change
Total Liabilities & Shareholders Equity	$11.09M	$12.31M
YoY Change	-9.92%	34.82%

Cashflow Statement

Concept	2017 Q1	2016 Q1
OPERATING ACTIVITIES
Net Income	-$3.232M	-$4.095M
YoY Change	-21.07%	97.72%
Depreciation, Depletion And Amortization	$61.58K	$61.64K
YoY Change	-0.1%	111.49%
Cash From Operating Activities	-$3.350M	-$3.620M
YoY Change	-7.46%	37.12%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$28.64K
YoY Change	-100.0%	-83.65%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$0.00	-$30.00K
YoY Change	-100.0%	-83.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	6.300M	-80.00K
YoY Change	-7975.0%
NET CHANGE
Cash From Operating Activities	-3.350M	-3.620M
Cash From Investing Activities	0.000	-30.00K
Cash From Financing Activities	6.300M	-80.00K
Net Change In Cash	2.950M	-3.730M
YoY Change	-179.09%	32.27%
FREE CASH FLOW
Cash From Operating Activities	-$3.350M	-$3.620M
Capital Expenditures	$0.00	$28.64K
Free Cash Flow	-$3.350M	-$3.649M
YoY Change	-8.19%	29.61%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q1	nuro	Clinical Study Obligations ClinicalStudyObligations	103000	USD
CY2016Q1	nuro	Closing Price Of Shares ClosingPriceOfShares	1.79
CY2016Q4	nuro	Common Stock Warrants CommonStockWarrants	4641	USD
CY2017Q1	nuro	Common Stock Warrants CommonStockWarrants	171651	USD
CY2016Q4	nuro	Common Stock Warrants Fair Value Disclosure CommonStockWarrantsFairValueDisclosure	4641	USD
CY2017Q1	nuro	Common Stock Warrants Fair Value Disclosure CommonStockWarrantsFairValueDisclosure	171651	USD
CY2017Q1	nuro	Restricted Cash Collateral Letters Of Credit RestrictedCashCollateralLettersOfCredit	507381	USD
CY2017Q1	dei	Amendment Flag AmendmentFlag	false
CY2017Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2017Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2017Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
CY2017Q1	dei	Document Period End Date DocumentPeriodEndDate	2017-03-31
CY2017Q1	dei	Document Type DocumentType	10-Q
CY2017Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001289850
CY2017Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	10147721	shares
CY2017Q1	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2017Q1	dei	Entity Registrant Name EntityRegistrantName	NeuroMetrix, Inc.
CY2017Q1	dei	Trading Symbol TradingSymbol	NURO
CY2016Q4	nuro	Accrued Sales Return Provisions AccruedSalesReturnProvisions	488200	USD
CY2017Q1	nuro	Accrued Sales Return Provisions AccruedSalesReturnProvisions	323403	USD
CY2016Q4	nuro	Clinical Study Obligations ClinicalStudyObligations	25000	USD
CY2016Q1	nuro	Stock Issuance Settle Incentive Compensation Obligation StockIssuanceSettleIncentiveCompensationObligation	318761	USD
CY2017Q1	nuro	Stock Issuance Settle Incentive Compensation Obligation StockIssuanceSettleIncentiveCompensationObligation	0	USD
CY2016Q4	nuro	Technology Fees TechnologyFees	450000	USD
CY2017Q1	nuro	Technology Fees TechnologyFees	450000	USD
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	734048	USD
CY2017Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	404068	USD
CY2016Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	738729	USD
CY2017Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	949969	USD
CY2016Q4	us-gaap	Accrued Advertising Current AccruedAdvertisingCurrent	28100	USD
CY2017Q1	us-gaap	Accrued Advertising Current AccruedAdvertisingCurrent	70600	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1648731	USD
CY2017Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1394976	USD
CY2016Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	390800	USD
CY2017Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	161000	USD
CY2016Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	183438878	USD
CY2017Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	189562554	USD
CY2016Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	25000	USD
CY2017Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	25000	USD
CY2016Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	21617179	shares
CY2017Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	55227301	shares
CY2017Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8739901	shares
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	669	USD
CY2017Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	745204	USD
CY2016Q4	us-gaap	Assets Assets	8283891	USD
CY2017Q1	us-gaap	Assets Assets	11089340	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	7586923	USD
CY2017Q1	us-gaap	Assets Current AssetsCurrent	10463806	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12462872	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8739651	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3949135	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6897161	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6900000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-3723221	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	2948026	USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2017Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2017Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	6694901	shares
CY2017Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8739901	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	6694901	shares
CY2017Q1	us-gaap	Common Stock Value CommonStockValue	874	USD
CY2016Q1	us-gaap	Cost Of Revenue CostOfRevenue	1482513	USD
CY2017Q1	us-gaap	Cost Of Revenue CostOfRevenue	2697602	USD
CY2016Q4	us-gaap	Deferred Costs Current DeferredCostsCurrent	910595	USD
CY2017Q1	us-gaap	Deferred Costs Current DeferredCostsCurrent	966781	USD
CY2016Q4	us-gaap	Deferred Revenue And Credits Current DeferredRevenueAndCreditsCurrent	1247545	USD
CY2017Q1	us-gaap	Deferred Revenue And Credits Current DeferredRevenueAndCreditsCurrent	1571465	USD
CY2016Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	628236	USD
CY2016Q1	us-gaap	Depreciation Depreciation	61638	USD
CY2017Q1	us-gaap	Depreciation Depreciation	61579	USD
CY2016Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.00
CY2017Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.91
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	307471	USD
CY2017Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	521192	USD
CY2017Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	524521	USD
CY2017Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y
CY2016Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-94316	USD
CY2017Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-77601	USD
CY2016Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1424341	USD
CY2017Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1421782	USD
CY2016Q1	us-gaap	Gross Profit GrossProfit	792734	USD
CY2017Q1	us-gaap	Gross Profit GrossProfit	1608520	USD
CY2016Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	154971	USD
CY2017Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	0	USD
CY2016Q4	us-gaap	Liabilities Liabilities	3323127	USD
CY2017Q1	us-gaap	Liabilities Liabilities	3237091	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8283891	USD
CY2017Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	397682	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	379509	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-329980	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-251455	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	211240	USD
CY2016Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	317732	USD
CY2017Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-40034	USD
CY2016Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-223349	USD
CY2017Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	116968	USD
CY2016Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	424238	USD
CY2017Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-55379	USD
CY2016Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-142887	USD
CY2017Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-236859	USD
CY2016Q1	us-gaap	Interest And Other Income InterestAndOtherIncome	6705	USD
CY2017Q1	us-gaap	Interest And Other Income InterestAndOtherIncome	4257	USD
CY2016Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	630361	USD
CY2017Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	799177	USD
CY2016Q4	us-gaap	Inventory Net InventoryNet	1252238	USD
CY2017Q1	us-gaap	Inventory Net InventoryNet	1196859	USD
CY2016Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	466906	USD
CY2017Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11089340	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3318486	USD
CY2017Q1	us-gaap	Liabilities Current LiabilitiesCurrent	3065440	USD
CY2017Q1	us-gaap	Line Of Credit Facility Expiration Date1 LineOfCreditFacilityExpirationDate1	2018-01-15
CY2017Q1	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	2500000	USD
CY2017Q1	us-gaap	Line Of Credit Facility Remaining Borrowing Capacity LineOfCreditFacilityRemainingBorrowingCapacity	2000000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-76653	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	6302000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-28643	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	0	USD
CY2017Q1	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	154407	USD
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-3617925	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-3353974	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-4095255	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-3232400	USD
CY2016Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-4095255	USD
CY2017Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-7274082	USD
CY2016Q1	us-gaap	Operating Expenses OperatingExpenses	4989010	USD
CY2017Q1	us-gaap	Operating Expenses OperatingExpenses	4922778	USD
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-4196276	USD
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-3314258	USD
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	220752	USD
CY2017Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	207869	USD
CY2016Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	0	USD
CY2017Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	0	USD
CY2016Q4	us-gaap	Other Deferred Credits Current OtherDeferredCreditsCurrent	619309	USD
CY2017Q1	us-gaap	Other Deferred Credits Current OtherDeferredCreditsCurrent	826261	USD
CY2016Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	28643	USD
CY2017Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
CY2016Q1	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	0	USD
CY2017Q1	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	4041682	USD
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2017Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1646821	USD
CY2017Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1419817	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	164262	USD
CY2016Q1	us-gaap	Proceeds From Repurchase Of Equity ProceedsFromRepurchaseOfEquity	-76653	USD
CY2017Q1	us-gaap	Proceeds From Repurchase Of Equity ProceedsFromRepurchaseOfEquity	6302000	USD
CY2016Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	45879	USD
CY2017Q1	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	79104	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	532706	USD
CY2017Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	471127	USD
CY2016	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	488200	USD
CY2017Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	323403	USD
CY2016Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1156790	USD
CY2017Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	903284	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-178478801	USD
CY2017Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-181711201	USD
CY2016Q1	us-gaap	Revenues Revenues	2275247	USD
CY2017Q1	us-gaap	Revenues Revenues	4306122	USD
CY2016Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2407879	USD
CY2017Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2597712	USD
CY2016Q1	us-gaap	Share Based Compensation ShareBasedCompensation	66012	USD
CY2017Q1	us-gaap	Share Based Compensation ShareBasedCompensation	66496	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	4960764	USD
CY2017Q1	us-gaap	Stockholders Equity StockholdersEquity	7852249	USD
CY2016Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	4090358	shares
CY2017Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	8007901	shares
CY2017Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during reporting periods. Actual results could differ from those estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001628280-17-003952-index-headers.html	Edgar Link	pending
0001628280-17-003952-index.html	Edgar Link	pending
0001628280-17-003952.txt	Edgar Link	pending
0001628280-17-003952-xbrl.zip	Edgar Link	pending
a10q3312017exhibit311.htm	Edgar Link	pending
a10q3312017exhibit312.htm	Edgar Link	pending
a10q3312017exhibit32.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
nuro-20170331.xml	Edgar Link	completed
nuro-20170331.xsd	Edgar Link	pending
nuro-20170331_cal.xml	Edgar Link	unprocessable
nuro-20170331_def.xml	Edgar Link	unprocessable
nuro-20170331_lab.xml	Edgar Link	unprocessable
nuro-20170331_pre.xml	Edgar Link	unprocessable
nuro03312017_10-q.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NURO
NeuroMetrix, Inc. Stock $nuro

2017 Q1 Form 10-Q Financial Statement

#000162828017003952 Filed on April 20, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NURO NeuroMetrix, Inc. Stock $nuro

2017 Q1 Form 10-Q Financial Statement

#000162828017003952 Filed on April 20, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NURO
NeuroMetrix, Inc. Stock $nuro